CNB0 Stock Overview
A biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Fortress Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.66 |
| 52 Week High | US$16.50 |
| 52 Week Low | US$4.36 |
| Beta | 1.8 |
| 11 Month Change | -18.25% |
| 3 Month Change | -37.87% |
| 1 Year Change | -58.02% |
| 33 Year Change | -78.82% |
| 5 Year Change | n/a |
| Change since IPO | -78.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| CNB0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.3% | 2.2% | -1.9% |
| 1Y | -58.0% | -9.6% | 12.3% |
Return vs Industry: CNB0 underperformed the German Biotechs industry which returned -9.8% over the past year.
Return vs Market: CNB0 underperformed the German Market which returned 12.3% over the past year.
Price Volatility
| CNB0 volatility | |
|---|---|
| CNB0 Average Weekly Movement | 18.8% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CNB0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CNB0's weekly volatility has increased from 14% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 186 | Lindsay Rosenwald | www.fortressbiotech.com |
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea.
Fortress Biotech, Inc. Fundamentals Summary
| CNB0 fundamental statistics | |
|---|---|
| Market cap | €39.78m |
| Earnings (TTM) | -€44.89m |
| Revenue (TTM) | €75.28m |
0.5x
P/S Ratio-0.9x
P/E RatioIs CNB0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNB0 income statement (TTM) | |
|---|---|
| Revenue | US$82.62m |
| Cost of Revenue | US$97.72m |
| Gross Profit | -US$15.09m |
| Other Expenses | US$34.18m |
| Earnings | -US$49.27m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.84 |
| Gross Margin | -18.27% |
| Net Profit Margin | -59.64% |
| Debt/Equity Ratio | -479.6% |
How did CNB0 perform over the long term?
See historical performance and comparison